Cost-Effectiveness of Empagliflozin (Jardiance) in the Treatment of Patients with Type 2 Diabetes Mellitus (T2DM) in the UK Based on Empa-Reg Outcome Data
Abstract
Authors
I Daacke P Kandaswamy A Tebboth A Kansal O Reifsnider